PF-Atlas › Clinical Trials › NCT03724955

Pilot E2 for Hypogonadal Women With CFBD

Estradiol 2 mg · Phase 4

Registry ID
NCT03724955
Phase
Phase 4
Status
Withdrawn
Drug / intervention
Estradiol 2 mg
Sponsor
Emory University
Start
2019-04
Locations
1

About this trial

The study is a prospective, double blinded, placebo controlled, randomized study to evaluate the effects of daily oral estrogen supplements on bone health, sexual and reproductive health, quality of life and markers of inflammation and lung function when given to hypogonadal women with Cystic Fibrosis related Bone Disease (CFBD).

View NCT03724955 on ClinicalTrials.gov →

Explore related

All Estradiol 2 mg trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03724955 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.